MAPT and Alzheimer disease: Pharmacological or genetic targeting of ER stress may represent a strategy for attenuation of the continuous generation of Aβ- and p-tau-associated neuronal cell death and neuroinflammation, which, in turn, may improve memory deficits and synaptic plasticity in AD.